17
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T10629 | Btk inhibitor 2 | BGB-3111 analog | BTK |
Btk inhibitor 2 (BGB-3111 analog) is a BTK inhibitor. | |||
T8636 | Ibrutinib deacryloylpiperidine | IBT4A,5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMine | BTK |
Ibrutinib deacryloylpiperidine (IBT4A) is a highly selective Bruton’s tyrosine kinase (BTK) irreversible inhibitor with an IC50 of 0.5 nM. | |||
T9304 | (S)-Sunvozertinib | N-[5-[[4-[5-Chloro-4-fluoro-2-(2-hydroxypropan-2-yl)anilino]pyrimidin-2-yl]amino]-2-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-4-methoxyphenyl]prop-2-enamide,DZD9008 | EGFR , HER |
(S)-Sunvozertinib (DZD9008) is a rationally designed selective, irreversible EGFR/HER2 inhibitor. | |||
T35330 | BTK inhibitor 1 | BTK | |
BTK inhibitor 1 (Compound 27) is a BTK inhibitor (IC50: 0.11 nM) with an inhibitory effect on B-cell activation in hWB with an IC50 of 2 nM. | |||
T38960 | QL-X-138 | Virus Protease , MNK , BTK | |
QL-X-138 is a potent and selective BTK and MNK dual kinase inhibitor that binds covalently to BTK and non-covalently to MNK.The IC 50 s of QL-X-138 against BTK, MNK1 and MNK2 kinases are 9.4 nM, 107.4 nM and 26 nM, respe... | |||
T38960L | QL-X-138 HCl | QL-X-138 HCl(1469988-63-3 Free base) | MNK , BTK |
QL-X-138 HCl is a novel selective and highly potent BTK/MNK dual-kinase inhibitor with anticancer activity that binds covalently to BTK and noncovalently to MNK. QL-X-138 HCl inhibited BTK, MNK1, and MNK2 kinases. QL-X-1... | |||
T4263 | BAY 61-3606 | Syk inhibitor IV | Apoptosis , Syk |
BAY 61-3606 (Syk inhibitor IV) is a potent, ATP-competitive, reversible, and highly selective inhibitor of Syk tyrosine kinase activity (Ki= 7.5 nM), exhibiting no inhibitory effect against Btk, Fyn, Itk, Lyn, and Src. | |||
T73463 | NX-2127 | NX2127,NX 2127 | BTK |
NX-2127 (ETX2514 Triethylamine) is an orally active BTK inhibitor that induces degradation of mutant BTKC481S in cells.NX-2127 has potent antiproliferative activity and inhibits the proliferation of BTKC481S mutant TMD8 ... | |||
T15725 | Lck inhibitor 2 | Others | |
Lck inhibitor 2 is a bis-anilinopyrimidine inhibitor of tyrosine kinases including LCK, BTK, LYN, SYK, and TXK (IC50s: 13nM, 9nM, 3nM, 26nM, and 2nM for Lck, Btk, Lyn, Btk, and Txk respectively). | |||
T9813 | JAK3/BTK-IN-2 | JAK , BTK | |
JAK3/ BTk-in-2 is a potent JAK3/BTK inhibitor. JAK3/ BTk-in-2 inhibits both BTK and JAK3, which are two important targets IN autoimmune diseases. JAK3/ BTk-in-2 simultaneously inhibits the BTK/JAK3 signaling pathway, sho... | |||
T15365 | G-744 | BTK | |
G-744 is a selective and orally active inhibitor of Btk (IC50: 2 nM). G-744 is well-tolerated, metabolically stable. It also has an efficacious to treat arthritis. | |||
T73303 | BTK-IN-17 | ||
BTK-IN-17 is a selective, orally active inhibitor of Bruton's Tyrosine Kinase (BTK) with an inhibition concentration (IC50) value of 13.7 nM. It effectively reduces the expression of phosphorylated BTK at Tyrosine 223 (p... | |||
T63229 | ITK inhibitor 6 | ||
ITK inhibitor 6 is a selective and potent ITK inhibitor that acts on ITK (IC50: 4 nM), BTK (IC50: 133 nM), JAK3 (IC50: 320 nM), EGFR (IC50: 2360 nM), LCK (IC50: 155 nM). ITK inhibitor 6 inhibited the phosphorylation of P... | |||
T37085 | Luxeptinib | ||
Luxeptinib (CG-806) is a novel pan-FLT3/pan-BTK inhibitor that is administered orally. It exhibits potent and reversible inhibition of these enzymes, acting through a non-covalent mechanism. Luxeptinib effectively induce... | |||
T73366 | BLK-IN-2 | ||
BLK-IN-2 is a potent, selective, and irreversible inhibitor of B-Lymphoid tyrosine kinase (BLK), demonstrating significant efficacy with an IC50 of 5.9 nM. Additionally, it exhibits an inhibitory effect on BTK (Bruton's ... | |||
T73942 | (Rac)-IBT6A hydrochloride | ||
(Rac)-IBT6A hydrochloride is a racemic mixture comprising IBT6A hydrochloride, which itself is an impurity of Ibrutinib. This compound plays a role in the synthesis of both the IBT6A Ibrutinib dimer and the IBT6A adduct ... | |||
T83911 | CYY292 | ||
CYY292 is a chemical compound acting as an inhibitor of PDGFRα, PDGFRβ, FGFR1, -2, and -3, with respective IC50 values of 5.35, 4.6, 28, 28, and 78 nM. It exhibits selectivity over FGFR4 (IC50 > 1,000 nM) while also targ... |